Baird Medical Fosters Advanced Physician Training at International Thyroid Microwave Ablation Workshop in Malaysia

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) participated in a two-day Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz, National University of Malaysia on Oct 1–2, 2025.

The immersive program combined lectures, complex case discussions and hands-on training with mannequins and live patient cases led by Proctor Dr. Shuhang Xu and HCTM faculty Dr. Adi Syazni and Prof. Shahrun Niza. Baird Medical supplied expertise and support to advance physician skills in minimally invasive Microwave Ablation (MWA) and to promote wider clinical adoption of MWA therapy in the region.

NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful participation in the Thyroid Microwave Ablation Workshop held at the Hospital Canselor Tuanku Muhriz (HCTM) of The National University of Malaysia.

The immersive two-day workshop, held from October 1–2, 2025, brought together leading surgeons and endocrinologists for intensive, hands-on training. Led by a distinguished faculty, Proctor Dr. Shuhang Xu, endocrinologist at Nanjing University of Traditional Chinese Medicine, alongside HCTM's B&E Surgeons Dr. Adi Syazni and Prof. Shahrun Niza, the program featured a rigorous curriculum encompassing theoretical lectures, complex case discussions, and practical training sessions using both mannequins and live patient cases.

Baird Medical's participation reflects its commitment to advancing innovative medical technologies and ensuring their effective adoption worldwide. The workshop served as a vital platform for local physicians to refine their MWA skills under the guidance of esteemed international experts, marking a significant step in the global expansion of this minimally invasive therapy. Baird Medical continues to play an integral role in empowering physicians to deliver MWA treatments safely and effectively.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-fosters-advanced-physician-training-at-international-thyroid-microwave-ablation-workshop-in-malaysia-302589997.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) do at the Thyroid Microwave Ablation Workshop in Malaysia on Oct 1–2, 2025?

Baird Medical participated by supporting an immersive two-day workshop featuring lectures, complex case discussions and hands-on MWA training with mannequins and live patients.

Who led the faculty at the BDMD-supported MWA workshop in Malaysia?

The faculty was led by Proctor Dr. Shuhang Xu with HCTM surgeons Dr. Adi Syazni and Prof. Shahrun Niza.

How does the Oct 2025 Malaysia workshop affect BDMD's business strategy?

The workshop supports BDMD's stated goal of promoting global adoption of its Microwave Ablation technology through physician training and education.

Where and when was the Thyroid Microwave Ablation Workshop that BDMD participated in?

The workshop took place at Hospital Canselor Tuanku Muhriz, National University of Malaysia on October 1–2, 2025.

What training formats were used at the BDMD-supported MWA workshop?

Training included theoretical lectures, complex case discussions and practical sessions using mannequins and live patient cases.